January 1st, 2024, MediLink Therapeutics solemnly announced the official appointment of Mr. Jason (Jia) Li as the company's chief financial officer (CFO). Mr. Li will report to Dr. Tongtong (Tony) Xue, Chairman and CEO of the company, and will be responsible for the overall financial planning and management, corporate finance and IPO, development strategy and other financial work, so as to promote the internationalization process and further steady development of the company's business, and address more unmet clinical needs.
Mr. Jason Li
Mr. Li has over 20 years of experience in corporate finance, capital markets and financial management. Prior to joining MediLink Therapeutics, Mr. Li served as CFO at RemeGen, where he played an important role in the completion of the pre-IPO financing, IPOs in both Hong Kong and the STAR market, overall financial planning, and management. Mr. Li had more than 15 years of working experience at global financial institutions such as Goldman Sachs (Asia), Morgan Stanley (Hong Kong), Barclays Capital (New York), assisting clients in various equity and debt financing, as well as cross-border M&A projects. Mr. Li has a MBA degree from the University of Chicago Booth School of Business, as well as Bachelor’s and Master’s degrees in Accountancy from the University of Wisconsin-Madison.
“I am very glad to join MediLink”, Mr. Li said, “as a leading biotech company with strong innovative capabilities, MediLink has already built a very strong foundation, deep pipeline and established a unique advantage in the ADC field. I look forward to joining the family and working with the world-class team in helping the company to quickly transition from a biotech to a biopharmaceutical company and achieve its globalization goals.
"We warmly welcome Mr. Li to join our team," said Dr. Xue. "MediLink currently has ongoing clinical trials in both the US and China, and we have established collaborations with leading pharmaceutical companies worldwide, as well as the completion of Series B financing. I believe Mr. Li's extensive experience and expertise in the healthcare industry, capital markets, and financial management will greatly accelerate our efforts to make our drugs globally available to patients as soon as possible."
About MediLink Therapeutics
MediLink Therapeutics founded in 2020, is a clinical stage biotech company focused on developing globally competitive conjugated drugs. MediLink has built a differentiated proprietary Tumor Microenvironment Activable LINker-payload (TMALIN®) ADC technology platform. It can generate homogeneous ADC, and further improve the therapeutic window in treatment of solid tumors. MediLink focuses their clinical drug development on unmet medical needs and will continuously expand into new disease areas to serve the global patients.
MediLink is headquartered in Suzhou and has established R&D subsidiaries in Shanghai and Boston.
MediLink Therapeutics Announces Latest Business Progress with Nona Biosciences
MediLink Therapeutics Announces Worldwide Collaboration and License Agreement with Roche to develop next-generation ADC in Oncology